Hong Kong start-up tests single-injection gene editing for inherited eye diseases
In short
- A local start-up is testing a gene-editing therapy for a group of inherited eye diseases.
- The therapy aims to act on these diseases at their genetic source.
- The article examines what it would take to turn the therapy into a treatment patients can access.
Why it's good news
Inherited eye diseases often have limited treatment options, so a therapy aimed at the genetic source is a meaningful direction. The source describes the work as testing and does not report approval or patient results. The piece focuses on the steps needed before patients could receive it.
From South China Morning Post
In the third of a four-part Health Matters wellness series on frontier medicine in Hong Kong, Fiona Sun examines how a local start-up is testing a gene-editing therapy that could tackle a group of inherited eye diseases at their genetic source and what it will take to turn it into a treatment patients can access. For 15 years, Professor Zheng Zongli has worked to make gene-editing therapies safe enough to treat diseases with limited treatment options. His path has taken him from a PhD in medical...